Sponge on a string cancer test endorsed for NHS rollout in England
Patients swallow a capsule that dissolves to release a sponge collecting oesophageal cells in seven minutes without sedation, Nice says device lets health service focus scarce endoscopy capacity on those who need it most
Images
A Cytosponge test, one of those used to help diagnose oesophageal cancer. (PA Media)
PA Media
Thousands of people in England with long-term acid reflux could be offered a "sponge on a string" test for oesophageal cancer after the treatment watchdog Nice recommended it for NHS use in new draft guidance. The endorsement is the first to be issued under the National HealthTech Access Programme, a scheme created to identify new technologies and decide whether the health service should adopt them routinely. More than 9,000 people a year are diagnosed with oesophageal cancer in the UK, and the diagnosis usually comes late, when the disease is harder to treat.
The procedure takes about seven minutes. The patient swallows a capsule attached to a string; the capsule dissolves in the stomach and releases a small sponge, which is pulled back up through the oesophagus, collecting cells from its lining for laboratory analysis. It involves no sedation and can be administered in GP surgeries, pharmacies and community diagnostic centres. Nice's committee found that patients prefer it to endoscopy, in which a camera on a thin tube is passed down the throat.
Two versions of the technology, Cytosponge and EndoSign, were recommended. Both check for Barrett's oesophagus, a condition in which stomach acid damages the lining of the food pipe and cells can begin growing abnormally. Barrett's affects an estimated 1 to 2 per cent of adults, is common among people with persistent reflux, and most people who have it never develop cancer. The tests also give those who do have it a way to monitor the condition.
The case that carried the recommendation was as much about capacity as about detection. "The new technology has the potential to make testing easier for patients while helping the NHS focus valuable endoscopy capacity on those who need it most," said Professor Jonathan Benger, chief executive of Nice. Peter Johnson, national clinical director for cancer at NHS England, said thousands of people had already benefited from the test in NHS pilots, and that an easier check would free up resources to find cancers at an earlier stage. The sponge sorts patients: only those whose cell samples look concerning go on to the camera.
Whether the sorting reaches everyone it should now depends on the programme the endorsement inaugurates. Thomas Slater, Nice's director of healthtech, called the recommendation "an important milestone", adding that the programme should support "consistent adoption of high-impact technologies across the country, ensuring they deliver benefits for patients and value for taxpayers". A programme whose job is to insist on adoption that is consistent across the country is a recognition of what tends to happen without one: a device that works stays where it was piloted.
The recommendation currently exists as draft guidance. The sponge takes seven minutes to find what the health service has been finding too late.